Loading…
Loading…
HZNP (Horizon Therapeutics Public Limited Company) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Amgen has not been a great performer in the last two years. Investors became and remain skeptical of MariTide's prospects in obesity, type 2 diabetes, and other related indications. I continue to see MariTide's monthly dosing as a strong selling point and expect that addition of dose escalation to phase 3 trial design will improve its tolerability.
Amgen on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics.
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.
We believe that AMGN has overpaid for HZNP's pipeline, since most of its upside potential is attributed to price increases instead of the expanding TAM. The growing debt may also pose headwinds to its profitability and subsequently, dividend growth and balance sheet deleveraging. Then again, it appears that Mr. Market is still convinced about AMGN' profitable growth ahead, as demonstrated by the stock's immense bullish support.
Amgen said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics after it received the go-ahead from the U.S. Federal Trade Commission (FTC) last month on certain conditions.
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?
We're now into September, and that means many investors wonder if the September effect will be in place. This speaks to the historical trend of stocks underperforming in September compared to other months.
No recent filings indexed.